Skip to search formSkip to main contentSkip to account menu

CDK2/5/9 Inhibitor CYC065

Known as: CYC065, Cyclin Dependent Kinase Inhibitor 2/5/9 CYC065 
An orally bioavailable inhibitor of cyclin dependent kinases 2, 5 and 9 (CDK2/5/9), with potential antineoplastic and chemoprotective activities… 
National Institutes of Health

Related topics

Related topics

4 relations
Cyclin-Dependent KinasesNCIt Antineoplastic Agent TerminologyNegative Regulation of Cell CyclePositive Regulation of Apoptosis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma
Glioblastoma (GBM) is the most common primary brain tumor with no available cure. As previously described, seliciclib, a first… 
2019
2019
Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS
Cyclin dependent kinases (CDKs) are critical for cell cycle regulation and transcriptional elongation. Dysregulated CDKs have… 
2018
2018
Abstract CT037: Phase I safety, pharmacokinetic and pharmacodynamic study of CYC065, a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953)
Background: CYC065 is a potent and selective inhibitor of CDK2 and CDK9. CDK2 drives cell cycle transition and activates major… 
2017
2017
Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer
Background The first generation CDK2/7/9 inhibitor seliciclib (CYC202) causes multipolar anaphase and apoptosis in lung cancer… 
2017
2017
Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer
Activation of CDK2 in triple negative breast cancer (TNBC) can contribute to non-canonical phosphorylation of a TGFβ signaling… 
2016
2016
Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo
Background:Clinical options for patients harbouring advanced/recurrent uterine serous carcinoma (USC), an aggressive variant of… 
2015
2015
CYC065, potential therapeutic agent for AML and MLL leukaemia
2015
2015
Abstract 3103: Cyclin E amplification predicts sensitivity of primary Uterine Serous Carcinoma (USC) cell lines to the cdk2 inhibitor CYC065
We evaluated the in vitro effectiveness of the cdk2 inhibitor CYC065 on multiple primary chemotherapy-resistant USC cell lines… 
2013
2013
Blockbuster dreams for Pfizer's CDK inhibitor
187 encouraging. However, the different CDK isoforms might be useful in different indications,” he says. “One size does not fit… 
2010
2010
CYC065, a Potent Derivative of Seliciclib Is Active In Multiple Myeloma In Preclinical Studies
Abstract 2999 Multiple myeloma (MM) is a treatable but incurable hematological malignancy and novel targeted therapies are under… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)